top of page
ConSynance Logo

ConSynance Therapeutics is a clinical-stage, biopharma company focused on rare central nervous system diseases.  ConSynance’s lead candidate, CSTI-500, is a Phase II ready, best-in-class Triple Monoamine Reuptake Inhibitor for Prader-Willi Syndrome, a rare genetic neurodevelopmental disorder with no adequate treatment.  To learn about Prader-Willi Syndrome, please visit


Our 2nd candidate, CSTI-100, is a Phase II ready, first-in-class, Melanin-Concentrating-Hormone Receptor 1 (“MCHR1”) inhibitor for PWS as well as for Non Alcoholic Steatohepatitis (NASH).


Please come back to visit our new website soon!


In the meantime, please contact us by email

bottom of page